Aktis Oncology filed on Friday with the U.S. Securities and Exchange Commission to raise up to $100 million in an initial public offering, saying it plans to list on the Nasdaq under the symbol AKTS. The Boston-based company is a Phase 1 biotech developing targeted alpha-emitting radiopharmaceuticals for solid tumors.
The company’s lead candidate, Ac-AKY-1189, targets Nectin-4-expressing cancers and is enrolling about 150 patients in a multi-site U.S. Phase 1b trial, with preliminary results expected in the first quarter of 2027. A second program, Ac-AKY-2519, targets B7-H3-expressing tumors and has an investigational new drug filing planned for 2026. Aktis also manages multiple domestic and international isotope supply partnerships, maintains a discovery collaboration for additional miniprotein radioconjugate programs, and is investing in an internal cGMP facility slated to be operational in 2026.
Founded in 2020, Aktis reported $6 million in revenue for the 12 months ended September 30, 2025. J.P. Morgan, BofA Securities, Leerink Partners and TD Cowen are the joint bookrunners on the offering. No pricing terms were disclosed.
Leave a Reply